Health and wellness company Rapid Nutrition plc (Euronext Growth Paris:ALRPD) announced on Tuesday that it has been chosen as a key partner in the Osteoarthritis Prevention Study (TOPS) led by Wake Forest University.
This project, receiving USD17.1m in funding from major health organisations, is the largest investigation into osteoarthritis prevention through weight loss and exercise in women. The five-year study, led by Wake Forest University's Department of Health and Exercise Science, aims to enrol 1,230 women aged 50 and above, focusing on those at risk of osteoarthritis due factors such as overweight status.
Rapid Nutrition's participation underscores its commitment to advancing scientific research and promoting women's health globally, the company said.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration